logo

For the Inventor, By the Inventor

Berlin, Germany

Epigenomics Ag


USPTO Granted Patents = 68

% Expired Patents = 54.4



Trademarks = 3

Forward Citations = 482

Loading Chart...
Loading Chart...

75 inventors (with patents filed for the assignee):

goldMedal Kurt Berlin (27 out of 27 patents)

silverMedal Reimo Tetzner (18 out of 19 patents)

bronzeMedal Fabian Model (14 out of 14 patents)

4.  Catherine E Lofton-Day (12 out of 12 patents)

5.  Juergen Distler (12 out of 12 patents)

6.  Ralf Lesche (11 out of 12 patents)

7.  Andrew Z Sledziewski (10 out of 10 patents)

8.  Matthias Schuster (10 out of 12 patents)

9.  Alexander Olek (10 out of 12 patents)

10.  Matthias Ballhause (9 out of 9 patents)

11.  Dimo Dietrich (9 out of 12 patents)

12.  Thomas Hildmann (6 out of 7 patents)

13.  Xiaoling Song (6 out of 6 patents)

14.  Jörn Lewin (4 out of 6 patents)

15.  Joern Lewin (4 out of 4 patents)


Core Competencies:
CpG Methylation
Cancer Diagnosis
Cell Proliferative Disorders
Gene Expression
Methylation Patterns
Bisulfite Conversion
DNA Amplification
Prostate Cancer
Breast Cancer
Methylated DNA
Nucleic Acids
PCR Techniques

68 patents:

1. 11345966 - Methods for detecting CpG methylation and for diagnosing cancer (2022-05-31),
2. 11261499 - Methods and nucleic acids for determining the prognosis of a cancer subject (2022-03-01),
3. 11186879 - Methods and nucleic acids for analyses of cellular proliferative disorders (2021-11-30),
4. 10731215 - Method for determining the presence or absence of methylation in a sample (2020-08-04),
5. 10626462 - Methods and nucleic acids for determining the prognosis of a cancer subject (2020-04-21),
6. 10385402 - Methods and nucleic acids for analyses of cellular proliferative disorders (2019-08-20),
7. 9988683 - Method and nucleic acids for the analysis of colon cell proliferative disorders (2018-06-05),
8. 9957575 - Methods for detecting CpG methylation and for diagnosing cancer (2018-05-01),
9. 9939441 - Methods and nucleic acids for analyses for cellular proliferative disorders (2018-04-10),
10. 9868756 - Method for bisulfite treatment (2018-01-16),
11. 9863001 - Method for the detection of cytosine methylations in DNA (2018-01-09),
12. 9850532 - Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders (2017-12-26),
13. 9719131 - Method for determining the degree of methylation of defined cytosines in genomic DNA in the sequence context of 5'-CpG-3′ (2017-08-01),
14. 9695478 - Methods and nucleic acids for the analyses of cellular proliferative disorders (2017-07-04),
15. 9670546 - Methods and nucleic acids for analyses of cell proliferative disorders (2017-06-06),
Epigenomics AG, based in Berlin, specializes in DNA methylation analysis, focusing on the development of innovative diagnostic solutions for cancer and cell proliferative disorders. The company leverages advanced technologies such as bisulfite conversion and DNA amplification to analyze methylation patterns, which are critical for understanding gene expression and disease mechanisms. With a strong emphasis on prostate cancer diagnostics, Epigenomics aims to enhance early detection and personalized treatment options through its cutting-edge research and development efforts.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Epigenomics Ag
68 Patents

#19 in D-1000 Berlin

#842 in Germany

#10,873 in the World

Berlin, DE
Berlin, Germany

Epigenomics Ag

Forward Citations = 482

75 inventors:

goldMedal Kurt Berlin (27 out of 27 patents)

silverMedal Reimo Tetzner (18 out of 19 patents)

bronzeMedal Fabian Model (14 out of 14 patents)

4.  Catherine E Lofton-Day (12 out of 12 patents)

5.  Juergen Distler (12 out of 12 patents)

Please report any incorrect information to [email protected]
Loading…